News & Press

‍

Subscribe to get the latest clinical and R&D news

Thanks! You're subscribed.
Oops! Something went wrong while submitting the form.
  • March 2025
    |
    Press Release
    Gradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation BurdenGradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden
  • February 2025
    |
    Press Release
    Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil® (Gemogenovatucel-T)Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil® (Gemogenovatucel-T)
  • January 2024
    |
    Press Release
    Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic CancersGradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers
  • December 2023
    |
    Press Release
    Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer TreatmentGradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment
  • November 2023
    |
    News Article
    Texas backs Carrollton firm working on ovarian cancer drug with $10 million grantTexas backs Carrollton firm working on ovarian cancer drug with $10 million grant
  • November 2023
    |
    Press Release
    Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of TexasGradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas
  • October 2023
    |
    Press Release
    Gradalis hosted KOL Discussion: Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian CancerGradalis hosted KOL Discussion: Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian Cancer
  • October 2023
    |
    Press Release
    Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum Sensitive Recurrent Ovarian Cancer on October 25, 2023Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum Sensitive Recurrent Ovarian Cancer on October 25, 2023
  • September 2023
    |
    Press Release
    Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews PublicationGradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication
  • June 2023
    |
    Press Release
    Gradalis Announces Peer-Reviewed Publication Demonstrating Potential of Novel 3D Scaffold Tissue Technology to Expand Vigil PlatformGradalis Announces Peer-Reviewed Publication Demonstrating Potential of Novel 3D Scaffold Tissue Technology to Expand Vigil Platform
  • March 2023
    |
    Press Release
    Gradalis to Participate in the Cantor Fitzgerald Future of Oncology SymposiumGradalis to Participate in the Cantor Fitzgerald Future of Oncology Symposium
  • March 2023
    |
    Press Release
    Gradalis Announces Publication in Clinical Cancer Research Featuring Positive Results from a Study Evaluating Vigil® in Combination Therapy for Patients with Recurrent Ewing's SarcomaGradalis Announces Publication in Clinical Cancer Research Featuring Positive Results from a Study Evaluating Vigil® in Combination Therapy for Patients with Recurrent Ewing's Sarcoma
  • February 2023
    |
    Press Release
    Gradalis to Present at the 2023 BIO CEO & Investor ConferenceGradalis to Present at the 2023 BIO CEO & Investor Conference
  • December 2022
    |
    Press Release
    Gradalis Receives Clearance to Begin Pivotal Phase 3 Clinical Trial of Vigil® (gemogenovatucel-T) in Patients With Advanced Ovarian Cancer in the U.S.Gradalis Receives Clearance to Begin Pivotal Phase 3 Clinical Trial of Vigil® (gemogenovatucel-T) in Patients With Advanced Ovarian Cancer in the U.S.
  • December 2022
    |
    Press Release
    Gradalis Appoints Eric Hall as Chief Financial OfficerGradalis Appoints Eric Hall as Chief Financial Officer
  • October 2022
    |
    Press Release
    Gradalis to Present at the 2022 Cell & Gene Meeting on the MesaGradalis to Present at the 2022 Cell & Gene Meeting on the Mesa
  • October 2022
    |
    Press Release
    Gradalis Announces Publication of Two Studies Demonstrating the Positive Results of Vigil® in Combination with Checkpoint InhibitorsGradalis Announces Publication of Two Studies Demonstrating the Positive Results of Vigil® in Combination with Checkpoint Inhibitors
  • September 2022
    |
    Press Release
    Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company's Immuno-Oncology Treatment, VigilGradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company's Immuno-Oncology Treatment, Vigil
  • September 2022
    |
    Press Release
    Gradalis KOL Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®Gradalis KOL Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®
  • September 2022
    |
    News Article
    Gradalis' Autologous Immunotherapy Shows Promise in Certain Ovarian Cancer PatientsGradalis' Autologous Immunotherapy Shows Promise in Certain Ovarian Cancer Patients
  • August 2022
    |
    Press Release
    Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated with Vigil®Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated with Vigil®
  • June 2022
    |
    Press Release
    Gradalis Appoints Steven Engle as Chief Executive OfficerGradalis Appoints Steven Engle as Chief Executive Officer
  • February 2022
    |
    Press Release
    Gradalis and University of Michigan collaboration to utilize a patient's cancer cells to create personalized therapeutics to treat cancerGradalis and University of Michigan collaboration to utilize a patient's cancer cells to create personalized therapeutics to treat cancer
  • March 2021
    |
    Press Release
    Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancerPhase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer
  • January 2021
    |
    Press Release
    Gradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet OncologyGradalis Announces Publication of Phase 2b VITAL trial of Vigil® demonstrating RFS and OS advantage in women with first-line platinum-responsive BRCA1 and BRCA2 wild-type advanced ovarian cancer in The Lancet Oncology
  • December 2020
    |
    News Article
    Dr. Rod Rocconi on Med School Watercooler: Significant Results for Ovarian Cancer PatientsDr. Rod Rocconi on Med School Watercooler: Significant Results for Ovarian Cancer Patients
  • December 2020
    |
    News Article
    Lancet Oncology: Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trialLancet Oncology: Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial
  • June 2020
    |
    News Article
    Gradalis at ASCO Virtual Scientific Forum - Randomized double-blind placebo-controlled trial of primary maintenance GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (VITAL study) in stage III/IV ovarian cancerGradalis at ASCO Virtual Scientific Forum - Randomized double-blind placebo-controlled trial of primary maintenance GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy (VITAL study) in stage III/IV ovarian cancer
  • April 2020
    |
    News Article
    Frontline Maintenance Vigil Immunotherapy Improves RFS in Ovarian CancerFrontline Maintenance Vigil Immunotherapy Improves RFS in Ovarian Cancer
  • June 2019
    |
    News Article
    Cancer Vaccine Developed In North Texas Could Be 'As Simple As A Flu Shot'Cancer Vaccine Developed In North Texas Could Be 'As Simple As A Flu Shot'
  • March 2019
    |
    Press Release
    Gradalis Announces Medical Leadership Team PromotionGradalis Announces Medical Leadership Team Promotion
  • November 2018
    |
    Press Release
    Gradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology GroupGradalis® Presents Initial Data from Phase II U.S. Trial for Ewing’s sarcoma at the Annual Meeting of the Children’s Oncology Group
  • October 2018
    |
    News Article
    Gradalis® implements L7 Informatics’ Enterprise Science Platform as part of initiating their Phase 3 Study of Vigil™ in Ewing’s sarcomaGradalis® implements L7 Informatics’ Enterprise Science Platform as part of initiating their Phase 3 Study of Vigil™ in Ewing’s sarcoma
  • August 2018
    |
    Press Release
    Gradalis® Announces Initiation of Phase 3 Study of Vigil™ in Ewing’s sarcomaGradalis® Announces Initiation of Phase 3 Study of Vigil™ in Ewing’s sarcoma
    Load more

    See how we can help

    Contact us

    About

    Product

    Get Help

    Gradalis, Inc.
    2545 Golden Bear Drive, Suite 110, Carrollton, TX 75006
    (214) 442-8100 
phone     (214) 442-8101 fax
    info@gradalisinc.com
    Cookie Policy | Terms & Conditions | © Copyright 2022 Gradalis, Inc.